UK Markets closed

Valneva SE (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
24.41+1.19 (+5.14%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close24.83
Open25.63
Bid19.51 x 1800
Ask26.55 x 1400
Day's range24.00 - 24.71
52-week range19.45 - 67.84
Volume7,388
Avg. volume15,584
Market cap1.294B
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)-3.06
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est65.93
  • Globe Newswire

    Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate

    Saint Herblain (France), May 25, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The final analysis included six-month follow-up data and confirmed the topline results reported in December 2021. The VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent imm

  • Zacks

    Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA

    Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.

  • Motley Fool

    Why Dynavax Stock Blasted 16% Higher Today

    What happened Several days after experiencing a pleasant share price pop on good regulatory news, Dynavax (NASDAQ: DVAX) repeated the feat on Thursday. An important partner for the company reported an encouraging development that morning, also in the regulatory sphere.